# Program 1 Architecture Review Track Phase F1 - Phase A/B/C/D/E Input Summary

Status: documentation-only summary of Architecture Review Track inputs.

## Phase A inputs

Phase A established synthetic-only architecture boundaries, permitted future discussion areas, prohibited runtime paths, data classification preview, read-only vs write-capable conceptual distinction, human-in-the-loop responsibility preview, and a future approval dependency map.

## Phase B inputs

Phase B established conceptual module separation, the synthetic documentation layer boundary, future read-only layer boundary, future clinical review layer boundary, prohibited write-capable layer boundary, prohibited patient communication boundary, prohibited appointment mutation boundary, deferred security/audit/authorization layer, and prohibited coupling map.

## Phase C inputs

Phase C established the synthetic entity model, conceptual data-flow model, allowed synthetic trace paths, prohibited real-data flow paths, read-only conceptual flow boundary, write-back and mutation prohibition trace, security/audit/auth conceptual flow limits, and boundary trace matrix.

## Phase D inputs

Phase D established the conceptual read-only reference boundary, non-mutation model, prohibited read access paths, prohibited write-back and mutation paths, read-only vs operational access distinction, and synthetic reference trace matrix.

## Phase E inputs

Phase E established the human-in-the-loop responsibility model, clinical accountability boundary, autonomous clinical behavior prohibition, clinician review and decision separation, patient instruction and communication prohibition, accountability dependency map, and clinical boundary matrix.

## Current limitation

Phase F uses these inputs only for documentation-only, synthetic-only security, authorization, and audit boundary review. Phase F does not authorize runtime security enforcement, runtime authentication, runtime authorization, RBAC, audit capture, access logging, policy enforcement, approval/clearance/override capability, production access, clinical deployment, real-data use, PHI/PII processing, or go-live.
